PMID: 20608141
Question: PSA repeatedly fluctuating levels are reassuring enough to avoid biopsy?
Correct Answer: no

======================= Launch the MCC process =======================
PMID: 20608141
Question: PSA repeatedly fluctuating levels are reassuring enough to avoid biopsy?

----- GPT's initial response -----
GPT is reasoning the answer...


**1. Question Analysis**
- **Core Content:** The question seeks to determine whether repeatedly fluctuating prostate-specific antigen (PSA) levels can be considered sufficiently reassuring to forgo a biopsy.
- **Key Information to Identify:** The study's findings regarding prostate cancer (PC) detection rates in patients with fluctuating PSA levels (flu-PSA) compared to those with steadily increasing PSA levels (si-PSA). Additionally, the effectiveness of PSA-related metrics (PSA Slope, PSAV, PSADT) in predicting cancer detection should be assessed.

**2. Evidence Evaluation**
- **Research Results:** The study involved 211 patients undergoing at least a second biopsy. Out of these, 82 had fluctuating PSA levels and 129 had steadily increasing PSA levels. The key findings are:
  - **Cancer Detection Rate:** No significant difference between flu-PSA and si-PSA groups.
  - **Clinical and Pathological Stage:** No significant differences between the two groups.
  - **Gleason Score:** The si-PSA group with cancer had a higher Gleason score.
  - **PSA Metrics:** PSA Slope, PSAV, and PSADT were not effective in differentiating cancer detection in flu-PSA patients.
- **Strength and Reliability:** The study's sample size of 211 patients provides a moderate level of reliability. However, the abstract does not mention randomization or controlling for other confounding factors.
- **Relevance:** The evidence directly addresses the research question by comparing cancer detection rates in fluctuating versus steadily increasing PSA levels.

**3. Conclusion**
Based on the study, fluctuating PSA levels do not result in a lower prostate cancer detection rate compared to steadily increasing PSA levels. Additionally, PSA-related metrics do not aid in distinguishing cancer presence in patients with fluctuating PSA. Therefore, fluctuating PSA levels alone should not be considered sufficient reason to avoid a biopsy.

**4. Final Answer:**
**My final choice is: "no"**
GPT selected: no

----- Qwen's initial response -----
Qwen is reasoning the answer...


**1. Question Analysis**  
The question asks whether repeatedly fluctuating PSA levels are sufficient to avoid biopsy. The key is determining if fluctuating PSA (flu-PSA) reduces the need for biopsy compared to steadily increasing PSA (si-PSA), based on cancer detection rates and other clinical outcomes.  

**2. Evidence Evaluation**  
The study compared 82 flu-PSA patients and 129 si-PSA patients who underwent repeat biopsy after an initial negative result. Results showed:  
- **No significant difference** in prostate cancer (PC) detection rates between the two groups at repeat biopsy.  
- PSA Slope, PSA velocity (PSAV), and PSA doubling time (PSADT) were not useful for predicting cancer detection in either group.  
- The si-PSA group with cancer had higher Gleason scores, but cancer detection rates and tumor stages were similar between groups.  

These findings indicate that fluctuating PSA levels do not lower the risk of harboring prostate cancer compared to steadily rising PSA. Thus, avoiding biopsy based on fluctuating PSA alone is not supported.  

**3. Conclusion**  
Since the study explicitly states no difference in cancer detection rates between flu-PSA and si-PSA groups, fluctuating PSA levels are **not** reassuring enough to avoid biopsy. The evidence directly contradicts the idea that fluctuating PSA reduces the necessity for biopsy.  

**4. Final Answer:**  
**My final choice is: "no"**
Qwen selected: no

----- Deepseek's initial response -----
DeepSeek is reasoning the answer...

**1. Question Analysis**  
The question asks whether fluctuating PSA (flu-PSA) levels are sufficient to avoid prostate biopsy. Key information to evaluate includes whether flu-PSA correlates with lower cancer detection rates compared to steadily increasing PSA (si-PSA) and whether PSA-related metrics (slope, velocity, doubling time) predict cancer risk.

**2. Evidence Evaluation**  
- The study found **no significant differences** in prostate cancer (PC) detection rates between flu-PSA and si-PSA groups.  
- PSA slope, velocity (PSAV), and doubling time (PSADT) were **not predictive** of cancer detection in flu-PSA patients.  
- The si-PSA group with cancer had higher Gleason scores, but clinical/pathological stages were similar between groups.  
- The abstract explicitly concludes that fluctuating PSA levels do not reduce cancer detection risk at repeat biopsy, and PSA metrics are unhelpful for risk stratification.  

**3. Conclusion**  
The evidence strongly indicates that fluctuating PSA levels do not lower the likelihood of cancer detection compared to steadily increasing PSA. Since the study found no reassurance in flu-PSA for avoiding biopsy, the answer is **"no"**.

**4. Final Answer**  
**My final choice is: no**
DeepSeek selected: no

Initial consensus: All models selected no